Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

8,559 total articles

Newmont After the Rally: Downgrade but Keep a Spot in Your Portfolio

Newmont After the Rally: Downgrade but Keep a Spot in Your Portfolio

<p>Newmont (NEM) remains one of the safest ways to own gold exposure through an operating gold major: strong free cash flow, low leverage and attractive returns on capital. Today I downgrade the stock from Buy to Hold but recommend a tactical long-on-dip trade for disciplined traders. The thesis: own Newmont for balance-sheet strength and capital r…

Silvercorp (SVM): Cheap Relative to Project Value — A Long Trade Backed by a $522M Gold PEA and Growing Production Optionality

Silvercorp (SVM): Cheap Relative to Project Value — A Long Trade Backed by a $522M Gold PEA and Growing Production Optionality

Silvercorp is a complex mid-tier precious-metals miner that now offers a clear asymmetric trade: a market cap of ~$2.74B against a $522M after-tax NPV Condor PEA, steady Chinese silver-lead-zinc cashflow and an expanding project pipeline. We lay out an actionable long trade (entry $12.00, stop $9.50, target $30.00) for a long-term horizon (180 trad…

Newmont Is Printing Cash — A Tactical Long While Gold Momentum Recovers

Newmont Is Printing Cash — A Tactical Long While Gold Momentum Recovers

Newmont has turned rock into cash: $7.3B of free cash flow, a sub-0.2 debt/equity ratio and double-digit returns on capital give the company both optionality and room to return capital. With gold still above pre-surge levels and miners trading on reasonable multiples (P/E ~19, EV/EBITDA ~9.9), we like a tactical long in NEM for a mid-term swing whi…

M/I Homes: A Defensive Growth Long in a Tough Housing Patch

M/I Homes: A Defensive Growth Long in a Tough Housing Patch

M/I Homes (MHO) combines a low-teens ROE, positive free cash flow and conservative leverage with a sub-10x P/E multiple and diversified regional footprint. In a housing market under pressure from higher rates, MHO's balance sheet, mortgage services unit and valuation profile create an asymmetric risk/reward for a mid-term long trade. Entry $141.11,…

Vanda After the Bysanti Pop: A Measured Long with a Clear Exit

Vanda After the Bysanti Pop: A Measured Long with a Clear Exit

Vanda Pharmaceuticals (VNDA) has ripped higher on the Bysanti approval news, trading at $8.39 with heavy volume and a refreshed commercial story. The company’s market cap sits near $495M and revenue trends show modest growth, but negative free cash flow and a history of losses mean this is a high-risk, reward-managed long. This trade idea lays out …

Nike Setup: Buy the Dip for a 180-Day Rebound

Nike Setup: Buy the Dip for a 180-Day Rebound

Nike is trading below key moving averages after a pullback that priced in tariff headwinds and softer China demand. With a $92.5B market cap, $2.48B of free cash flow and a 2.46% dividend yield, the balance sheet and brand give Nike room to recover. Catalysts over the next 3-6 months - including a Supreme Court ruling easing tariff risk (02/23/2026…

InnovAge - A Risk-Reward Trade: Regulatory Overhang Is Priced In, But Operational Momentum Could Surprise

InnovAge - A Risk-Reward Trade: Regulatory Overhang Is Priced In, But Operational Momentum Could Surprise

InnovAge (INNV) has been through litigation and volatility; recent moves suggest much of the bad news is already priced into the stock. Revenue growth and improving margins give a plausible path to upside, but high valuation multiples and regulatory sensitivity make this a medium-risk trade. Enter on weakness, size carefully, and use a defined stop…

Wegovy’s Momentum Is Underpriced: A Mid-Term Long on Novo Nordisk

Wegovy’s Momentum Is Underpriced: A Mid-Term Long on Novo Nordisk

Novo Nordisk (NVO) has been hammered on trial headlines and short-term fears, but underlying demand for weight-loss therapies and expanding oral formulations support a mid-term trade. At $47.42 the stock reflects pessimism about 2026 sales that may already be priced in. This trade targets a rebound as Wegovy adoption steadies and market growth expe…